Introduction
The Non Hodgkin lymphomas comprise a diverse group of malignancies that are currently subclassified according to the state of differentiation of the B cells, the characteristics of the morphology and by the presence of specific cytogenetic abnormalities. Microarray gene expression profiling analyses have identified molecular heterogeneity and gene signatures, or "Indicator" genes, predictive of tumour behaviour and patient outcome in many cancer types including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). [1] [2] [3] [4] Application of this approach to follicular lymphoma identified two prognostic signatures based upon non malignant tumor infiltrating cells indicative of the host immune response rather than characteristics of the tumour cells. A predominant T-cell response was associated with good prognosis and a macrophage response was in contrast associated with a poor prognosis. 2 Both of these immune signatures provided independent utility from established clinical prognostic markers. Given the extremely variable outcome in FL there is an urgent need for validation of these immune signatures and for their translation to routine clinical use, which would allow better prognostication of outcome and would potentially direct and inform the application of more targeted molecular therapies in future.
Despite the promise of developing immune signatures in FL relatively few studies have validated gene expression profiling using established immunohistochemical methods [5] [6] [7] [8] [9] [10] , and none have used real-time PCR to measure the prognostic value of immune gene signatures using a clinically applicable methodology.
Measurement of gene expression using microarrays is difficult in routine practice 1 and there is a need for development of other, simpler, less expensive methods that are both sensitive and The polyA cDNA pool generated is also indefinitely renewable and as such represents a "molecular block". 11-13 The polyA cDNA can be then be assayed for the expression of particular genes, either by hybridization with cDNA microarrays 14 or by real-time PCR. Real-time PCR measurement however, enables more precise quantitation of the expression levels of specific Indicator genes. As such it is better suited for measurement in clinical practice, whilst also focussing on diagnostically relevant
Indicator genes. This approach thereby enables gene signatures to be detected within very small amounts of pathological material 15 and we have recently demonstrated its utility in diffuse large B-cell lymphoma and follicular lymphoma.
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In this study, we have used the same approach to measure immune gene signatures in 
Material and methods

Clinical samples
Sixty frozen lymph nodes (Ln), (with at least 5 years follow up) with a diagnosis of follicular lymphoma were obtained, with informed consent, from the archives of the Christie Hospital NHS Trust, Manchester, UK. Ethical permission for the study was granted by the North West
Multi-centre Research Ethics Committee and by the Central Manchester Research Ethics
Committee. The samples were selected from the archive on a sequential chronological basis, taking all samples for which consent was given, in the archive from 1995 backwards to 1989.
These were initially assessed for suitability on the basis of biopsy size, amount of necrosis and confidence of diagnosis. All cases unlikely to have sufficient material for analysis, with more than 10% necrosis or with uncertain or complex / mixed diagnoses were excluded.
Paraffin embedded sections from all cases were reviewed by two pathologists (RJB & LPM).
A diagnosis of follicular lymphoma was confirmed in all cases and biopsies in which there was morphological evidence of transformation were excluded from the study. There were thirty-three males and twenty-seven females with a median age of 66 years and an age range of 34 to 77 years. Forty five were dead and fifteen alive at the end of follow-up. None of the patients received Rituximab as first line treatment as this treatment was not available at the time during which the cases were collected. All material used in the study was collected at initial diagnosis, prior to treatment.
Immunohistochemistry
Standard immunohistochemistry was used for the following antibodies: CD3, CD4, CD7, CD8, CD10, CD20, CD21 and CD68. All antibodies were diluted to working concentration in DAKO Real Antibody Diluent (DAKO, Glostrup, Denmark); primary antibody working concentrations are shown in table 1. For each antibody detection was carried out using a DAKO Envision kit (DAKO, Glostrup, Denmark) with positivity disclosed by were counted using a mean of 3 high power fields for each case 5 .
Extraction of RNA and global amplification of Poly Adenylated mRNAs (PolyA RT-PCR)
The lymph nodes were homogenised using a Mixer Mill MM 300 (Qiagen, Crawley, West Sussex, UK). Total RNA was then extracted an RNeasy TM mini kit (Qiagen), as recommended by the manufacturer; DNase was used to remove the contaminating genomic DNA, and polyA RT-PCR carried out as previously described. 13, [19] [20] [21] Global amplification of cDNA corresponding to all expressed genes (polyA PCR), was carried out as previously reported.
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Specific RT PCR
The 35 Indicator genes were chosen from previously published candidates (Dave et al 
Taqman TM real-time quantitative PCR
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From For each gene, Taqman TM PCR was applied to 1ng PolyA cDNA from each sample and to 10 microlitres of serially diluted human genomic standards, using a Taqman TM Gold kit. All samples were analysed using an ABI Prism 7700 sequence detection system (Applied Biosystems, CA, USA). The copy number of each gene was determined by reference, after normalisation to Mhouse (below), of the real-time PCR expression level to human genomic DNA standards;
previously described in Sakhinia et al. genes (Mhouse) expression levels were divided by the highest mean value obtained in the experiment, resulting in a correction factor. All data was then normalised using this factor.
Statistical analysis
Kaplan-Meier survival analysis using a log rank test was performed against the normalised real-time PCR expression levels of each of the genes and against the percentage immunohistochemical postivity for the antibodies CD3, CD4, CD7, CD8, CD10, CD20 and CD21. For CD68 Kaplan-Meier survival analysis was performed for cases with either 15 or less or more than 15 CD68 positive cells per high power field.
Results
Immunohistochemistry
Measurement of the number of cells positive for CD3, CD4, CD7, CD8, CD10, CD20 and CD21
was performed by semi-automated image analysis using a spectral imager in view of the large number of positive cells in each case, whilst measurement of the number of CD68 positive cells was performed manually using the same method detailed in Farinha et al. 
PolyA PCR
PolyA cDNA was generated from mRNA extracted from all 60 lymph nodes. The copy number for each gene in each sample was highly reproducible over at least duplicate tests demonstrating reliability of the method. Specific PCR of these polyA cDNAs was positive for each of the selected Indicator genes, and bands of appropriate sizes were present in all samples, demonstrating presence of the target transcript in the polyA cDNA (data not shown). There was no statistically significant difference in the value of Mhouse for the different diagnostic groups (data not shown).
Survival analysis
Survival analysis was performed against real-time PCR expression levels and against immunopositivity for T-cell, B-cell and macrophage reactive antibodies. The data for each gene and for each antibody was grouped into 4 quartiles for Kaplan-Meier survival analysis. In this project we extended this method to measurement of the immune signature in follicular lymphoma, using real-time PCR to measure 35 Indicator genes reflective of T-cell and macrophage activation in polyA cDNAs prepared from 60 archived human frozen lymph nodes. In addition immunohistochemistry for a range of T-cell and macrophage markers was performed on parallel formalin fixed paraffin embedded tissue blocks from the same cases.
Real-time PCR was used to measure the expression levels of a wide range of genes indicative of T-cell and macrophage activation, including several genes abstracted from previous microarray studies demonstrating the importance of the immune response in FL.
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Expression levels were measured for 35 genes, increased levels of just one of which, namely CCR1 were associated with poorer outcome (p=0.013). In addition, comparison of the gene
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From expression level in patients alive or dead at the end of the study interval confirmed the importance of CCR1 as a predictor of outcome (p=0.009). Conversely, levels of CD3 were significantly higher in those alive compared to those who had died of at the end of the study (p=0.017).
Immunohistochemistical analyses demonstrated that high numbers of macrophages, identified by CD68 staining, were associated with a poor outcome, whereas high levels of CD7 positive Tcells were associated with a better outcome. High levels of CD3 positive T-cells were also associated with a better outcome, consistent with the finding of higher CD3 expression on those alive at the end of the period of study, whilst CD8 had no effect on survival. CD4 was negatively associated with survival in a quartile analysis but not when grouped together with upper and lower quartiles (see fig 2) . The reason for one quartile being significant is unclear although the quartiles do show a high degree of overlap. Whether this result is reproducible or biologically relevant remains unclear. Other markers, namely B-cell markers (CD20) and CD10 and CD21 appeared to have no effect on survival.
Our results are otherwise in keeping with previous published results demonstrating the importance of the immune signature in FL. CD7 was found to be present in the immune-response when comparing the T-cell and macrophage signatures. 2 We have tested for this using Cox multivariate analysis which identified CD7 as the principal predictor of survival, followed by the macrophage marker CD68.
Numbers of CD3 positive cells were significantly associated with survival when the upper and lower quartiles were grouped together. This concurs with the real-time PCR result for CD3 mRNA expression. Conversely neither CD7 or CD68 mRNA expression levels were significantly associated with survival, although protein expression levels were for both. Table 2 List of genes measured by real-time PCR (TaqMan primers and probes for each are detailed in supplementary data). For each gene the reference from which it was selected is given (details in references); additional lineage markers selected are indicated as such.
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